Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Sanjeev Khindri"'
Autor:
Philippe Bareille, Susan Tomkins, Varsha Imber, Mohammed Tayob, Karen Dunn, Rashmi Mehta, Sanjeev Khindri
Publikováno v:
Allergy, Asthma & Clinical Immunology, Vol 16, Iss 1, Pp 1-9 (2020)
Abstract Background To evaluate the effects of fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis, and the safety and tolerability of fluticasone furoate treatment in children with asthma. Methods This was a randomized, double-
Externí odkaz:
https://doaj.org/article/0ce32c7bcbe24897b56dc8229228dcd6
Publikováno v:
ERJ Open Research, Vol 2, Iss 2 (2016)
This study compared the efficacy and safety of once-daily umeclidinium 62.5 µg with once-daily glycopyrronium 50 µg in patients with moderate-to-severe chronic obstructive pulmonary disease. This was a 12-week, multicentre, randomised, open-label,
Externí odkaz:
https://doaj.org/article/a1a36365efe947539a8c94c6543bc2be
Autor:
Kate Sully, Hannah Staunton, Susan A. Tomkins, Sanjeev Khindri, Rob Arbuckle, Henrik Svedsater, Linda Nelsen
Publikováno v:
Value in Health. 22:340-347
Introduction Diary-derived symptom score and rescue medication use endpoints, such as symptom-free days (SFDs) and rescue medication-free days (RFD), are frequently used as clinical trial endpoints. Estimates of meaningful change for SFDs and RFDs ha
Autor:
Ian Schneider, Geng Chen, David Tenero, Sanjeev Khindri, Malek Okour, Adeep Puri, Kathleen Port, Alessandro Berni
Publikováno v:
Clinical therapeutics. 41(6)
Purpose Pulmonary arterial hypertension (PAH) is a life-threatening disease that typically causes shortness of breath and exercise intolerance. Combination therapy with ambrisentan and tadalafil has proven to be more effective at preventing clinical
Autor:
Mohammed Tayob, Rashmi Mehta, Philippe Bareille, Varsha Imber, Susan A. Tomkins, Sanjeev Khindri, Karen Dunn
Publikováno v:
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
Allergy, Asthma & Clinical Immunology, Vol 16, Iss 1, Pp 1-9 (2020)
Allergy, Asthma & Clinical Immunology, Vol 16, Iss 1, Pp 1-9 (2020)
Background To evaluate the effects of fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis, and the safety and tolerability of fluticasone furoate treatment in children with asthma. Methods This was a randomized, double-blind, pl
Publikováno v:
ERJ Open Research, Vol 2, Iss 2 (2016)
This study compared the efficacy and safety of once-daily umeclidinium 62.5 µg with once-daily glycopyrronium 50 µg in patients with moderate-to-severe chronic obstructive pulmonary disease.This was a 12-week, multicentre, randomised, open-label, p
Autor:
Claudia Leemereise, Edith M. Hessel, Shuying Yang, Annabel Hogg, J. Nicole Hamblin, Andrea Ludwig-Sengpiel, Jon Robertson, Oliver Kornmann, Sanjeev Khindri, Mickael Montembault, Anthony Cahn, Yi Cui, Hannah Wajdner, Malcolm Begg
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 367(3)
Phosphoinositide 3-kinase δ (PI3Kδ) is a lipid kinase involved in leukocyte recruitment and activation. Activation of PI3Kδ has been linked to airway inflammation and asthma pathogenesis. This randomized, double-blind, placebo-controlled, crossove
Publikováno v:
Clinical therapeutics. 39(6)
A dry powder inhaler formulation of the inhaled corticosteroid fluticasone furoate (FF) is being evaluated for use in children. An important potential risk associated with the use of inhaled corticosteroids in children is growth suppression. Therefor
Autor:
Lilly Li, Corinne Emotte, Ralph Woessner, Sanjeev Khindri, Ji Jiang, Hu Pei, Ruobing Li, Hequn Yin
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Indacaterol is an inhaled, ultra-long-acting β2-agonist that provides 24-h bronchodilation with once-daily dosing in patients with chronic obstructive pulmonary disorder. This study evaluated the pharmacokinetics, safety, and tolerability of multipl
Autor:
Gregory, Feldman, François, Maltais, Sanjeev, Khindri, Mitra, Vahdati-Bolouri, Alison, Church, William A, Fahy, Roopa, Trivedi
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
Background The long-acting muscarinic antagonists umeclidinium (UMEC) and tiotropium (TIO) are approved once-daily maintenance therapies for COPD. This study investigated the efficacy and safety of UMEC versus TIO in COPD. Methods This was a 12-week,